Don't bother to try to get into this company now - Avis employé Employé (anonyme) Merck

1,0
14 avr. 2010
Employé (anonyme)
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Being able to perform research and help make a difference with sickness in this world is the best part of working for this company

Inconvénients

Layoffs and more layoffs! As this company integrates with SGP it is obvious that employees are no longer considered an asset by the senior management. With all the outsourcing of jobs it is obvious that $$ is more important than the employees to top management. As we are told no one should expect to have a long career at this company any more. In fact it seems that they want to get rid of the more experienced people as they cost more to keep if you have over 10 years at this company or older than 45 you had better look over your shoulder, as you have a big bulls eye on your back The company is outsourcing everything, research, sales, manufacturing and support staff all being outsourced. Pretty soon the only thing a Merck employee will do is to slap a Merck label on the bottle.

Découvrez plus d’avis sur Merck

5,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Excellent company to work with.

Inconvénients

No cons encountered so far

4,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Inconvénients

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Voir les avis par: Utile|Évaluation|Date|Tout